Three recent studies tackled strategies aimed at preventing recurrent Clostridium difficile infection (RCDI). Adding a single dose of bezlotoxumab—a monoclonal antibody that neutralized C difficile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results